The humble aspirin that you pop to ameliorate headache or a precaution against heart attack can also take on the dangerous colorectal cancer in people with a specific gene, a significant study shows.
"Individuals whose colons have high levels of a specific gene product - 15-hydroxyprostaglandin dehydrogenase (15-PGDH) RNA - dramatically reduce their chances of developing colorectal cancer by taking aspirin," said the researchers.
Aspirin, however, provides no benefit to individuals whose colons show low levels of 15-PGDH, the researchers added.
"If you looked at the folks from the study who had high 15-PGDH levels and took aspirin, they cut their risk of colon cancer by half," said Sanford Markowitz, a professor at Case Western Reserve School of Medicine in the US.
"If you looked at the folks from the study that were low for 15-PGDH, they did not benefit at all from taking aspirin," Markowitz added.
The extraordinary finding comes from a multi-institutional team that analysed data and other material from two long-term studies involving nearly 128,000 participants.
The study appeared in the journal Science Translational Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
